| Heart Failure (HF) |
1 |
1 |
| Heart |
0 |
0.63 |
| Arrhythmia |
0 |
0.59 |
| Quality of Life |
0 |
0.58 |
| Atrial Fibrillation |
0 |
0.55 |
| Cardiomyopathy |
0 |
0.55 |
| Cardiovascular Imaging |
0 |
0.55 |
| Hypertension |
0 |
0.55 |
| Adherence |
0 |
0.32 |
| Clinical Research |
0 |
0.21 |
| Brachial |
0 |
0.16 |
| Exercise |
0 |
0.16 |
| Type 2 Diabetes Mellitus |
0 |
0.99 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.12 |
| HIV Infection |
0 |
0.12 |
| ACE Inhibitor |
0 |
0.11 |
| Angiotensin II Receptor Blockade |
0 |
0.11 |
| Clinical Guidelines |
0 |
0.1 |
| Electrophysiology |
0 |
0.1 |
| Metabolism |
0 |
0.1 |
| Myocardial Infarction (MI) |
0 |
0.1 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.1 |
| Receptors |
0 |
0.1 |
| B-Type Natriuretic Peptide |
0 |
0.07 |
| Implantable Cardioverter-Defibrillator |
0 |
0.07 |
| Beta Blockers |
0 |
0.05 |
| Brain |
0 |
0.05 |
| Defibrillator |
0 |
0.05 |
| Ejection Fraction |
0 |
0.05 |
| Fatty Acids |
0 |
0.05 |
| Generics |
0 |
0.05 |
| Kansas |
0 |
0.05 |
| Mobility |
0 |
0.05 |
| New York |
0 |
0.05 |
| Sulfonylureas |
0 |
0.05 |
| Tennessee |
0 |
0.05 |